[go: up one dir, main page]

WO2007045660A1 - Phospholipase a2 secretee du groupe iii (spla2-iii) destinee a des traitement et diagnostic - Google Patents

Phospholipase a2 secretee du groupe iii (spla2-iii) destinee a des traitement et diagnostic Download PDF

Info

Publication number
WO2007045660A1
WO2007045660A1 PCT/EP2006/067519 EP2006067519W WO2007045660A1 WO 2007045660 A1 WO2007045660 A1 WO 2007045660A1 EP 2006067519 W EP2006067519 W EP 2006067519W WO 2007045660 A1 WO2007045660 A1 WO 2007045660A1
Authority
WO
WIPO (PCT)
Prior art keywords
spla2
iii
subject
compound
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/067519
Other languages
English (en)
Inventor
Shinji Hatakeyama
Ichiro Kudo
Makoto Murakam
Kae Tsutsumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2007045660A1 publication Critical patent/WO2007045660A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Definitions

  • the methods include a) determining at a first time point the expression level of a sPLA2-III polypeptide molecule in the subject; b) determining at a subsequent time point the expression of the sPLA2-III polypeptide in the subject; and c) comparing the expression level at the first time point with that at the subsequent time point, wherein a significant change in the expression level is an indication of the onset, progression, or regression of the coronary artery disease.
  • Figure 2A shows the serum sPLA2-III activity of sPLA2-III transgenic mice.
  • human tissue samples can be screened for the presence and/or absence of the sPLA2-III nucleic acid and/or polypeptides.
  • samples can comprise tissue samples, whole cells, cell lysates, or isolated nucleic acids, including, for example, needle biopsy cores, surgical resection samples, lymph node tissue, plasma, or serum.
  • nucleic acids extracted from these samples may be amplified using techniques well known in the art. The levels of sPLA2-III detected would be compared with those in a normal tissue sample.
  • the diagnostic method comprises determining whether a subject has a coronary artery disease by detecting the mRNA, cDNA or polypeptide level of sPLA2-III.
  • kits can also contain instructions for conducting the assays and for interpreting the results.
  • the kits can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to the sPLA2-III polypeptide or functional fragments thereof; and, optionally, (2) a second, different antibody which binds to either the sPLA2-III polypeptide or the first antibody and is conjugated to a detectable label.
  • Example 4 Effects of sPLA2-III on HDL.
  • LDL, d 1.019-1.063 g/mL
  • HDL, d 1.085-1.210 g/mL

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation de la sPLA2-III aux fins d'identification d'un composé thérapeutique à utiliser dans le traitement des coronaropathies. Le composé thérapeutique utilisé dans le traitement des coronaropathies peut être un oligonucléotide antisens, un ARNsi, un anticorps ou un composé chimique. L'invention concerne également l'utilisation de la sPLA2-III comme biomarqueur aux fins de diagnostic, pronostic, bilan d'extension et traitement des coronaropathies.
PCT/EP2006/067519 2005-10-19 2006-10-17 Phospholipase a2 secretee du groupe iii (spla2-iii) destinee a des traitement et diagnostic Ceased WO2007045660A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72821405P 2005-10-19 2005-10-19
US60/728,214 2005-10-19

Publications (1)

Publication Number Publication Date
WO2007045660A1 true WO2007045660A1 (fr) 2007-04-26

Family

ID=37685967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/067519 Ceased WO2007045660A1 (fr) 2005-10-19 2006-10-17 Phospholipase a2 secretee du groupe iii (spla2-iii) destinee a des traitement et diagnostic

Country Status (1)

Country Link
WO (1) WO2007045660A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059129A2 (fr) * 2000-02-11 2001-08-16 Centre National De La Recherche Scientifique (Cnrs) Nouvelle phospholipase a2 secretee mammalienne du groupe iii
WO2001064907A2 (fr) * 2000-03-02 2001-09-07 Incyte Genomics, Inc. Enzymes metabolisant les lipides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059129A2 (fr) * 2000-02-11 2001-08-16 Centre National De La Recherche Scientifique (Cnrs) Nouvelle phospholipase a2 secretee mammalienne du groupe iii
WO2001064907A2 (fr) * 2000-03-02 2001-09-07 Incyte Genomics, Inc. Enzymes metabolisant les lipides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EPO Proteins [online] 6 September 2001 (2001-09-06), "Sequence 2 from Patent WO0159129.", XP002418689, retrieved from EBI accession no. EPOP:AX212314 Database accession no. AX212314 *
JIN W ET AL: "Lipases and HDL metabolism.", TRENDS IN ENDOCRINOLOGY AND METABOLISM, vol. 13, no. 4, May 2002 (2002-05-01), pages 174 - 178, XP002418687 *
KUDO I ET AL: "Phospholipase A2 enzymes", PROSTAGLANDINS, vol. 68-69, August 2002 (2002-08-01), pages 3 - 58, XP004380613 *
MURAKAMI M ET AL: "Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A(2).", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 26, 1 July 2005 (2005-07-01), pages 24987 - 24998, XP002418686 *
MURAKAMI M ET AL: "New phospholipase A(2) isozymes with a potential role in atherosclerosis.", CURRENT OPINION IN LIPIDOLOGY, vol. 14, no. 5, October 2003 (2003-10-01), pages 431 - 436, XP008074643 *

Similar Documents

Publication Publication Date Title
Fu et al. Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism
Yoshimoto et al. The discovery of LOX-1, its ligands and clinical significance
Ramasamy Update on the laboratory investigation of dyslipidemias
EP2260301B1 (fr) Signatures géniques
US8703496B2 (en) Biological markers for longevity and diseases and uses thereof
US7108982B1 (en) Diagnostics and the therapeutics for macular degeneration
US20080118928A1 (en) Diagnostics and therapeutics for arterial wall disruptive disorders
Bus et al. Apolipoprotein C‐I plays a role in the pathogenesis of glomerulosclerosis
WO2017055627A1 (fr) Mutations apoc3 pour le diagnostic et la thérapie de la maladie héréditaire amyloïdose rénale
JP2014197006A (ja) 微量ヒト血漿タンパク質バイオマーカーの新規なパネルを使用した肝線維症の臨床診断
WO2015041987A1 (fr) Modulation des voies de l'efferocytose pour le traitement d'une maladie athérosclérotique
Nahon et al. Proteoglycan 4 regulates macrophage function without altering atherosclerotic lesion formation in a murine bone marrow-specific deletion model
Senatus et al. DIAPH1 mediates progression of atherosclerosis and regulates hepatic lipid metabolism in mice
Chen et al. Palmitoyl acyltransferase activity of ZDHHC13 regulates skin barrier development partly by controlling PADi3 and TGM1 protein stability
Hui et al. Role of matrix Gla protein in transforming growth factor-β signaling and nonalcoholic steatohepatitis in mice
Bubenek et al. Assessment of gene expression profiles in peripheral occlusive arterial disease
WO2012051301A1 (fr) Procédés pour identifier des modulateurs du métabolisme des triglycérides, pour moduler le métabolisme des triglycérides et pour identifier des sujets à risque pour le métabolisme anormal des triglycérides
WO2007045660A1 (fr) Phospholipase a2 secretee du groupe iii (spla2-iii) destinee a des traitement et diagnostic
EP2234639A2 (fr) Modification des taux de lipoprotéines haute densité (hdl) par modulation de la carboxylestérase 1
JP7239139B2 (ja) 肝硬変の診断方法、非アルコール性脂肪肝炎及び肝細胞がんの合併症の診断方法並びに非アルコール性脂肪肝炎及び食道胃静脈瘤の合併症の診断方法
US20100313285A1 (en) Altering High Density Lipoprotein Levels Through UDP-N-Acetyl-Alpha-D-Galactosamine: Polypeptide N-Acetlgalactosaminyltransferase (GALNT) Modulation
Qian et al. Involvement of USP7 in aggravating Kawasaki disease by promoting TGFβ2 signaling mediated endothelial-mesenchymal transition and coronary artery remodeling
EP2997383A1 (fr) Fgf23 utilisé en tant que biomarqueur en vue de prédire le risque de mortalité dû à une maladie du foie de stade final
WO2023120612A1 (fr) Agent thérapeutique ou prophylactique pour la crise cardiaque, la fibrose cardiaque ou l'insuffisance cardiaque, dans lequel htra3 est la cible thérapeutique
Yesiltepe et al. Human APOE variants in Alzheimer’s Disease and type III hyperlipoproteinemia: insights from Long-Evans knock-in rat models with humanized App and APOE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06807361

Country of ref document: EP

Kind code of ref document: A1